| Hidradenitis Suppurativa

Hadlima vs Amjevita

Side-by-side clinical, coverage, and cost comparison for hidradenitis suppurativa.

Deep comparison between: Hadlima vs Amjevita with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsAmjevita has a higher rate of injection site reactions vs Hadlima based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Amjevita but not Hadlima, including UnitedHealthcare

Category

Hadlima

Amjevita

At A Glance

RouteSC injection

FrequencyEvery other week

ClassTNF-alpha blocker

RouteSC injection

FrequencyEvery other week

ClassTNF-alpha antagonist

Indications

Rheumatoid Arthritis
Juvenile polyarthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Psoriasis vulgaris
Hidradenitis Suppurativa
Uveitis

Rheumatoid Arthritis
Juvenile arthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Psoriasis vulgaris
Hidradenitis Suppurativa
Uveitis

Dosing

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.

Juvenile polyarthritis SC every other week based on weight for patients 2 years and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg).

Crohn Disease Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction (80 or 160 mg Day 1, 40 or 80 mg Day 15), then 20 or 40 mg every other week starting Day 29.

Ulcerative Colitis 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.

Psoriasis vulgaris, Uveitis 80 mg initial dose, then 40 mg every other week starting 1 week after the initial dose.

Hidradenitis Suppurativa 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis Adults: 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.

Juvenile arthritis, Uveitis (pediatric, >=2 years) Weight-based SC every other week: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), 40 mg (>=30 kg).

Crohn Disease (adults) 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29.

Crohn Disease (pediatric, >=6 years) Weight-based: 80 mg Day 1 / 40 mg Day 15 / 20 mg every other week (17 to <40 kg); 160 mg Day 1 / 80 mg Day 15 / 40 mg every other week (>=40 kg).

Ulcerative Colitis Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.

Psoriasis vulgaris, Uveitis (adults) 80 mg SC initial dose, then 40 mg every other week starting one week after the initial dose.

Hidradenitis Suppurativa (adults) 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

Hidradenitis Suppurativa (adolescents >=12 years, >=30 kg) Weight-based: 80 mg Day 1 / 40 mg every other week from Day 8 (30 to <60 kg); 160 mg Day 1 / 80 mg Day 15 / 40 mg weekly or 80 mg every other week from Day 29 (>=60 kg).

Contraindications

—

Drug Interactions

1223View drug interactions

Adverse Reactions

Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, hyperlipidemia, flu syndrome, abdominal pain, laboratory test abnormalities.

Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.

Postmarketing Liver failure, hepatitis, autoimmune hepatitis, sarcoidosis, Merkel cell carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, systemic vasculitis, deep vein thrombosis.

Most common (>=5%) Injection site reactions, upper respiratory infection, sinusitis, headache, rash, nausea, urinary tract infection, flu syndrome, abdominal pain, back pain, hypertension.

Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.

Postmarketing Diverticulitis, large bowel perforations, pancreatitis, pyrexia, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis.

Pharmacology

TNF-alpha blocker; adalimumab-bwwd is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.

Adalimumab-atto is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, inhibiting TNF-mediated inflammatory and immune responses; it also lyses surface TNF-expressing cells in vitro in the presence of complement and modulates downstream biological responses including adhesion molecule expression (ELAM-1, VCAM-1, ICAM-1).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Hadlima